Development and Evaluation of New Choleretic Agent

Ferubko EV1,*, Rendyuk TD2, Dargaeva TD1, Nikolaev SM3

ABSTRACT

Background: The aim of the research is the determination of pharmacological activity during the development of the optimal way of a new choleretic agent obtaining. The multicomponent herbal medicinal product under the code name Hexaphyte (herbal multicomponent dry extract) is developed. It contains the following species of medicine plant raw materials: Helichrysum arenarium L., Tanacetum vulgare L., Rosa sp., Urtica dioica L., Mentha piperita L., Glycyrrhiza glabra L. in the ratio of 6:2:2:1:1. Materials and Methods: Herbal tea was extracted three times with hot water at the temperature of 75-85°C; water extracts were combined, filtered and dried. Hexaphyte was standardized by the content of phenolic compounds – sum of flavonoids in terms of luteolin standard and isosalipurposide standard. Phenolic compounds (flavonoids) are dominating substances (35-37%) in the obtained extract. The obtained multicomponent medicine under the code name Hexaphyte was administered per os in the experimental and therapeutic dose of 250 mg/kg to the laboratory animals having experimental induced damages of gallbladder and liver. Results: In Hexaphyte the content of the flavonoid sum (IFS) referred to luteolin standard at a wavelength of 350 nm was not less than 4%; CFS referred to isosalipurposide standard at a wavelength of 315 nm was not less than 15%. It was revealed in the results of the realized experiments that it has a choleretic effect superior in a number of indicators to the activity of the Allochol reference drug. The pharmacotherapeutic effect of Hexaphyte at experimental damages of gallbladder and liver is due to the presence of biologically active substances, mainly of phenolic nature. Conclusion: The obtained results of the research argue the feasibility of using the developed multicomponent medicine Hexaphyte containing biologically active substances of phenolic nature in the prevention and complex treatment of hepatobiliary system diseases.

Key words: Choleretic herbal medicine Hexaphyte, Experimental damage of liver and gallbladder, Preclinical studies, Choleretic activity.

INTRODUCTION

Cholecystitis is the common disease of the gastroduodenal zone. If the gallbladder inflammatory process is prolonged, functional and organic changes in the liver can occur.1 As known, the gallbladder and biliary tract diseases have the nature of a chronic course with seasonal exacerbations. In this regard, it is advisable to use herbal medicinal products for prevention and treatment.2,3 The range of herbal medicines with choleretic activity is limited, and it is represented by such drug preparations as Flamin, Caleflon, Hofitol, Allochol, etc.4 Therefore, the search and development of new effective multicomponent choleretic drugs are important.

Previously, we developed the choleretic herbal tea. Its composition and the ratio of the components were selected experimentally taking into account the significance of individual links in the mechanism of the liver, gall bladder, and biliary tract damages development.5,7 Flowers of dwarf everlasting and tansy (fam. Asteraceae) contain flavonoids that stimulate bile formation and have antispasmodic activity in relation to the smooth muscles of the gastrointestinal and biliary tracts.5,7 Leaves of peppermint (fam. Lamiaceae) contain flavonoids promoting digestion by stimulating the secretion of hydrochloric acid and enzymes in the stomach.7 Roots of liquorice (fam. Fabaceae) are rich in saponins having a pronounced anti-inflammatory effect and flavonoids with a moderate choleretic effect.19 Leaves of common nettle (fam. Urticaceae) and rose hips (fam. Rosaceae) contain a complex of biologically active substances that contribute to the metabolism normalization, stimulate tissue regeneration in the gastrointestinal tract, increase the body’s resistance and stimulate the liver detoxification function.10,11 Thus, according to the literature data, there is information about the anti-inflammatory, the antispasmodic and choleretic effects of biologically active substances that are components of dwarf everlasting and tansy flowers, rose hips, common nettle and of peppermint leaves, as well as liquorice roots. In regard to the above, in the scope of the task, the exploration of the choleretic activity of the mentioned herbal composition is promising and prognostic.

It is known that flavonoids, coumarins, xanthones, tannins, phenolic acids, phenolcarboxylic acids, etc. are classified as phenolic compounds. The content of biologically active substances in total extract preparations is usually calculated in terms of any dominant component. In the case of our choleretic herbal drug, the dominant components providing choleretic activity are luteolin (in tansy) and isosalipurposide (in dwarf everlasting). Given this

Cite this article: Ferubko EV, Rendyuk TD, Dargaeva TD, Nikolaev SM. Development and Evaluation of New Choleretic Agent. Pharmacogn J. 2020;12(5):962-6.
circumstance, in the normative documents developed for such means, the inclusion of such techniques is accepted. This approach is generally accepted in the development and standardization of herbal medicines. In this regard, we use the procedure for determining phenolic compounds to standardize the Hexaphyte (choleretic agent obtained from herbal tea) by the amount of biologically active substances (flavonoids).

The aim of the research is pharmacological activity determination during the development of an optimal way of a new choleretic agent obtaining.

**MATERIALS AND METHODS**

**Plant material**

The object of the research is herbal composition under the code name Hexaphyte containing flowers of dwarf everlast (*Helichrysum arenarium* L.), flowers of tansy (*Tanacetum vulgare* L.), rose hips (*Rosa sp.*), leaves of common nettle (*Urtica dioica* L.), leaves of peppermint (*Mentha piperita* L.), roots of liquorice (*Glycyrrhiza glabra* L.). Raw materials purchased in the pharmacy network of the Russian pharmaceutical company “Krasnogorsleksredstva” were used as the objects.

**Hexaphyte extract preparation**

To confirm the choleretic effect based on data of chemical composition the following method of the medicine obtaining is suggested. The herbal tea containing flowers of dwarf everlast, flowers of tansy, rose hips, leaves of common nettle, leaves of peppermint, and roots of liquorice in the ratio of 6:2:2:1:1 was extracted three times with water at the temperature of 75-85º C. The combined extracts are purified by filtration and dried. The resulting extract contains polysaccharides, flavonoids, carotenoids, organic acids, vitamins, macro- and microelements, essential oils, and other natural compounds.

**Flavonoid content (phenolic compounds) determination**

Dwarf everlast and tansy flowers are the main medicinal raw materials that are part of Hexaphyte and determines its choleretic effect. In this regard, the procedure of quantitative determination in Hexaphyte of the sum of biologically active substances (flavonoids) in terms of the dominant components of tansy (luteolin) and immortelle (isosalipurposide) using UV-spectrophotometry was developed. The absorption of Hexaphyte solutions in 20% ethanol is subject to the Beer–Lambert–Bouguer law from 0.000020 to 0.000160 g of Hexaphyte in 1 ml of solution. UV absorption spectra of the drug, luteolin, and isosalipurposide in 20% ethanol are presented in Figure 1.

An exact sample (about 0.050 g) of the extract is dissolved in a 50 ml volumetric flask in 20 ml of warm (40-60 ºC) purified water, 10.4 ml of 96% ethanol are added, the volume of the solution is adjusted to the mark with water and mixed thoroughly (solution A). 2.5 ml of solution A is transferred to a 25 ml volumetric flask and the volume of the flask is adjusted to the mark with water and mixed thoroughly (solution A). The optical density of solution B was measured on a UV-1800 spectrophotometer (Shimadzu, Japan) at a wavelength of 350 nm (for luteolin) and 315 nm (for isosalipurposide) in a cuvette with a layer thickness of 1 cm. 20% ethanol is used as a comparison solution. In parallel, the optical density of solutions of luteolin standard sample (GSO Pharmacopoeial Monograph 42-29-70-93 at a concentration of 5 µg/ml in 20% ethanol at a wavelength of 350 nm and isosalipurposide standard sample (GSO temporary Pharmacopoeial Monograph 42-36-72 at a concentration of 15 µg/ml 20% ethanol is measured at a wavelength of 315 nm. The content of the sum of flavonoids in % on absolutely dry raw materials X in terms of luteolin standard and isosalipurposide standard is calculated by the formula:

\[
X = \frac{A \cdot C \cdot V_1 \cdot V_2 \cdot 100}{A_0 \cdot a \cdot V \cdot l} \cdot \frac{100}{100 - w}
\]

where: \(A\) – optical density of the test solution
\(A_0\) – optical density of the state standard sample solution
\(a\) – sample of the drug in g
\(C\) – concentration of the solution of the standard sample in g/ml
\(V\) – volume of solution A taken for analysis, in ml
\(V_1; V_2\) – dilution in ml
\(l\) – cuvette layer thickness in cm
\(w\) – loss in mass upon drying, in%.

The extract under the code name Hexaphyte was standardized by the sum of flavonoids in terms of luteolin standard and isosalipurposide standard. The content of the flavonoid sum referred to luteolin standard at a wavelength of 350 nm is not less than 4%. The content of the flavonoid sum referred to isosalipurposide standard at a wavelength of 315 nm is not less than 15%. The dominating components of the extract obtained are phenolic compounds – flavonoids (35-37%).

**Animal studies**

The experiments were performed on 120 outbred mature male white rats with an initial body weight of 180-200 g, and on 40 Guinea pigs both male and female with an initial body weight of 400-500 g. The animals were obtained from the Federal State Budgetary Scientific Institution Biomedical Technology Research Center of the Federal Medical and Biological Agency of Russia; they lived in the vivarium and were provided with free access to food and water. Pharmacological studies were carried out according to "Rules for the work using experimental animals", "Regulations accepted by the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes", Order of the Ministry of Health of the Russian Federation No. 199n dated 04/01/2016 "On the approval of the rules of good laboratory practice", according to the norms of good laboratory practice.
Hexaphyte choleretic activity at predetermined experimental and therapeutic dose of 250 mg/kg has been under study using the models of experimental cholecystitis and D-galactosamine hepatitis. The herbal choleretic agent Allochol CJSC Vifitech (Russia) registered in the Russian State Register of Medicines at a dose of 250 mg/kg was applied as the reference preparation.

Experimental cholecystitis in guinea pigs was induced with intraperitoneal injections of hexenal in a dose of 50 mg/kg. An abdominal cavity was opened in guinea pigs, and then a partial sampling of bile was performed with thin injection needles; then 0.1 ml of a 3% solution of H₂O₂ provided by (LLC “Rosbio”, Russia, Pharmacopoeial monograph of the enterprise 42-4677-08) was injected into the gallbladder cavity. Acute liver damage was caused in rats by a single intraperitoneal injection of D-galactosamine hydrochloride (Sigma-Aldrich (Merck), USA, chemically pure) in a dose of 1.0 g/kg of body weight. The degree of choleretic activity of the extract (Sigma-Aldrich (Merck), USA, chemically pure) in a dose of 1.0 g/kg of body weight, starting from the 2nd day after the injection of hydrogen peroxide. Herbal preparation Allochol in a dose of 250 mg/kg of guinea pig weight was used as a reference drug. Animals of the experimental and prevention purposes in the experimental therapeutic dose of 250 mg/kg has been under study using the models of experimental cholecystitis and D-galactosamine hepatitis. The Hexaphyte choleretic activity at predetermined experimental and control group received purified water in the same volume according to a similar treatment plan. The results of the studies are shown in Table 1.

Under Hexaphyte action bile secretion rate in guinea pigs is accelerated at test day 3 by 25%, at day 7 – by 4%, at day 14 – by 22% compared to the control data. Reference drug-influenced bile secretion reaction in guinea pigs to a lesser extent. Thus, under experimental Hexaphyte pharmacotherapy of gallbladder damages in guinea pigs, reliably expressed the choleretic effect of the studied extract was revealed. Hexaphyte was slightly superior to Allochol in this type of pathological process according to the level of pharmacotherapeutic effect.

It is known that it is necessary to correct the main pathogenetic factors of damage to the organs of the hepatobiliary system in order to achieve full recovery, reduce the likelihood of relapse and chronicity. Hexaphyte impact on bile formation function of the liver in outbred white rats with D-galactosamine induced hepatitis has been under study as well.

Primary, the rats were arranged into the following groups: intact (10 rats); control (10 rats); experimental 1 (10 rats); experimental 2 (10 rats) ones. Animals of the first experimental group were administered with Hexaphyte into the stomach through a tube in an experimental and therapeutic dose of 250 mg/kg, once after the injection of the damaging agent. Animals of the second experimental group were administered with Allochol reference drug in the isoeffective dose of 500 mg/kg according to a similar regimen. The animals of the control group were provided with equimolecular amounts of purified water according to a similar treatment plan. The results of the studies are shown in Table 2.

Based on data presented in Table 2 we found out that study of bile formation function of the liver shown a statistically significant increase in the bile secretion rate due to Hexaphyte administration, more by 63% compared with the control. Allochol reference drug had a significantly pronounced choleretic effect, increasing the rate of choleresis by 33% compared with the control. Bile acid content in bile was more by 36% and 42% compared with the control under the administration of Hexaphyte and Allochol respectively.

Under Hexaphyte treatment, the content of glycocholic, glycochenodeoxycholic, and taurocholic bile acids in bile increased

### Table 1: Changes in bile secretion rate under Hexaphyte action at experimental cholecystitis in guinea pigs, (M ± m).

| Groups of animals | Bile secretion rate, mg/min per 100g of body weight | Intact, n=10 | Control (H₂O₂ + H₂O), n=10 | Experimental 1 (H₂O₂ + Hexaphyte 250 mg/kg), n=10 | Experimental 2 (H₂O₂ + Allochol 250 mg/kg), n=10 |
|-------------------|----------------------------------------------------|--------------|----------------------------|--------------------------------------------------|-----------------------------------------------|
|                   | day 3 | 5.2 ± 0.4 | 4.3 ± 0.1 | 5.4 ± 0.2 | 4.6 ± 0.3 |
|                   | day 7 | 5.4 ± 0.3 | 4.0 ± 0.2 | 5.9 ± 0.3 | 5.0 ± 0.2 |
|                   | day 14| 5.2 ± 0.2 | 5.0 ± 0.2 | 6.1 ± 0.3 | 5.3 ± 0.6 |
|                   | day 21| 5.1 ± 0.4 | 5.0 ± 0.2 | 5.0 ± 0.5 | 5.0 ± 0.3 |

**Note:** hereinafter * – P-values ≤0.05 represented significant differences between data of control and experimental groups

### Table 2: Hexaphyte impact on bile formation function of liver in outbred white rats with D-galactosamine induced hepatitis, (M ± m).

| Choleresis indices | Intact, n=10 | Control (D-galactosamine + H₂O₂), n=10 | Experimental 1 (D-galactosamine + Hexaphyte 250 mg/kg), n=10 | Experimental 2 (D-galactosamine + Allochol 250 mg/kg), n=10 |
|-------------------|--------------|----------------------------------------|--------------------------------------------------|-----------------------------------------------|
| Bile secretion rate, mg/min per 100g of body weight | 3.2 ± 0.1 | 3.0 ± 0.1 | 4.9 ± 0.3 | 4.0 ± 0.3 |
| Bile acid content in bile, mg % | 1453 ± 14.4 | 843 ± 60.4 | 1150 ± 50.0 | 1200 ± 55.0 |
| Taurocholic acid content in bile, mg % | 716 ± 86.3 | 373 ± 35.2 | 617 ± 46.0 | 627 ± 50.0 |
| Taurochenodeoxycholic acid content in bile, mg % | 356 ± 32.4 | 116 ± 16.8 | 195 ± 44.0 | 215 ± 40.5 |
| Glycocholic acid content on bile, mg % | 266 ± 28.8 | 80 ± 26.8 | 187 ± 12.9 | 197 ± 20.1 |
| Glycochenodeoxycholic acid content in bile, mg % | 70 ± 17.9 | 60 ± 13.4 | 85 ± 12.9 | 95 ± 15.2 |
| Bilirubin concentration in bile, µmol /L | 165.0 ± 10.0 | 230.0 ± 16.7 | 164.0 ± 5.5 | 175.2 ± 9.8 |
| Cholesterol concentration in bile, µmol /L | 300.0 ± 28.1 | 140.0 ± 6.7 | 225.0 ± 14.4 | 234.3 ± 10.3 |
significantly by 133%, 41%, and 68% respectively; and there was observed an accelerated cholesterol excretion with bile, more by 60% compared with the control. Sherlock S. et al. and Muriel P. found that experimental therapy of toxic liver lesions with hepatoprotective agents is characterized by a gradual restoration of the liver structure, a decrease in the manifestations of the mesenchymal inflammatory reaction and cholestatic disorders.27,28 Thus, multicomponent medicine Hexaphyte obtained has a significant choleretic effect in the D-galactosamine induced hepatitis model that is comparable in a number of indicators with the effect of the Allochol reference drug.

CONCLUSION

In the results of the conducted experiments, it was revealed that per os administration of multicomponent medicine under the code name Hexaphyte an experimental and therapeutic dose of 250 mg/kg to the laboratory animals having experimental induced damages of gallbladder and liver has a choleretic effect superior in a number of indicators to the activity of the Allochol reference drug.

The pharmacotherapeutic effect of Hexaphyte at experimental damages of gallbladder and liver is due to the presence of biologically active substances, mainly of phenolic nature. The obtained results of the research argue the feasibility of applying the developed multicomponent medicine Hexaphyte containing biologically active substances of phenolic nature in the prevention and complex treatment of hepatobiliary system diseases.

ACKNOWLEDGMENT

This paper was financially supported by "Russian Academic Excellence Project 5-100".

CONFLICTS OF INTEREST

None.

REFERENCES

1. Kharrazian D. Gastrointestinal Diseases: Recent Research and Commentary (translated by Bochagov V.). URL: applied-kinesiology.ru/book/107 (Accessed on 06.04.2020).

2. Korsun VF, Nikolaev SM, Ogrenich MA, Korsun EV, Bartonova EA, Sultanbekov BA. Medicinal plants and liver diseases: a guide to clinical herbal medicine. Moscow: Practical Medicine. 2014;327.

3. Lubsandorzhieva PNB. Development and standardization of herbal medicines for the treatment and prevention of digestive diseases. Ul'an-Ude: Publishing House of the BSC SB RAS. 2016:280.

4. State Register of Medicines of the Russian Federation. URL: https://grls.rosminzdrav.ru/ (Accessed on 07.04.2020).

5. Madrigal-Sartillán E, Madrigal-Bujaidar E, Álvarez-González I, Sumaya-Martínez MT, Gutiérrez-Salinas J, Bautista M, et al. Review of natural products with hepatoprotective effects. World J Gastroenterol. 2014;20:14787-804.

6. Ambriz-Perez DL, Leyva-Lopez N, Gutierr-Grijalva EP, Heredia JB. Phenolic compounds: natural alternative in inflammation treatment, A review. Cognet Food Agric. 2016;2:1-14.

7. Ag Agrawal AD. Pharmacological activities of flavonoids: a review. Int J Pharm Sci Nanotechnol. 2011;4:1394-8.

8. Dooley J (ed.) Sherlock’s Diseases of the Liver and Biliary System. 13th edition. London: Blackwell, 2018: 832.

9. Singh R, Shushi MAM, Belkheir A. Antimicrobial and antioxidant activities of Mentha piperita L. Arab J Chem. 2015;8:322-8.

10. Parvaiz M, Hussain K, Khalid S, Hussnain N, Iram N, Hussain Z, et al. A review: Medicinal importance of Glycyrrhiza glabra L. (Fabaceae family). Global J Pharmacol. 2014;8(1):8-13.

11. Joshi BC, Mukhiya M, Kalia AN. Pharmacognostical review of Urtica dioica L. Int J Green Pharm. 2014;8:201-9.

12. Orhan DD, Hatevlioglu A, Kupeli E, E. Yesilada E. In vivo anti-inflammatory and antinociceptive activity of the extract and fractions from Rosa canina L. fruits. J Ethnopharmacology. 2007;112:394-400.

13. State Pharmacopoeia of the Russian Federation XIV edition. URL: http://www.femb.ru/femb/pharmacopoea.php.

14. Ferubko EV, Nikolaev SM, Dargave TD. The holeretic agent, and method of its preparation. Patent No. 2700681 of the Russian Federation, IPC Codes A61K 36/185, A61K 36/28, A61K 36/738 A61K 36/354, A61K 36/484, A61P 1/16. Published 19.09.2019, Bulletin No 26 [in Russian].

15. Guidelines for preclinical studies of drugs. Part 1. M.: Grif i K, 2012:944 [in Russian].

16. Kuntz E, Kuntz H-D. Hepatology. Principles and practice: history, morphology, biochemistry, diagnostics, clinic, therapy. Berlin Heidelberg New York Springer Verlag. 2000;825.

17. Sherlock S, Dooley J. Diseases of the liver and biliary system. 13th edition. London: Blackwell. 2018;813.

18. Muriel P. Liver Pathophysiology: Therapies and Antioxidants. New York: Academic Press. 2017:914.

19. Nikolaev SM. Phytopharmacochemistry and disease phytopharmacoprophylaxis. Ul'an-Ude: Publishing House of the BGU. 2012:286 [in Russian].
GRAPHICAL ABSTRACT

ABOUT AUTHORS

- **Ferubko Ekaterina Vladimirovna**: Candidate of Medical Sciences, Head of the Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Russia, Moscow). Research interests: study of targeted pharmacological activity and action mechanism of biologically active substances to create highly effective herbal medicines based on it.

- **Rendyuk Tamara Danilovna**: Candidate of Pharmaceutical Sciences, Associate Professor, Department of Pharmaceutical Natural Sciences, Institute of Pharmacy, Sechenov First Moscow State Medical University of Ministry of Health of Russia (Russia, Moscow). Research interests: search for promising sources of biologically active substances and creation highly effective herbal medicines on this basis.

- **Dargaeva Tamara Darizhapovna**: Doctor of Pharmaceutical Sciences, professor, chief researcher at the Department of Phytochemistry and Standardization, All-Russian Research Institute of Medicinal and Aromatic Plants (Russia, Moscow). Research interests: search for promising sources of biologically active substances and creation highly effective herbal medicines on this basis.

- **Nikolaev Sergey Matveevich**: Doctor of Medical Sciences, professor, chief researcher at the Laboratory of Experimental Pharmacology of Institute of General and Experimental Biology of the Siberian Branch of the RAS (Russia, Ulan-Ude). Research interests: study of targeted pharmacological activity and action mechanism of biologically active substances to create highly effective herbal medicines based on it.

Cite this article: Ferubko EV, Rendyuk TD, Dargaeva TD, Nikolaev SM. Development and Evaluation of New Choleretic Agent. Pharmacogn J. 2020;12(5):962-6.